Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DYN - Dyne Therapeutics, Inc.

IEX Last Trade
24.01
-10.290   -42.857%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:19:13 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$34.30
-10.29
-30.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-0.08%
1 Month
-18.61%
3 Months
-31.28%
6 Months
-29.31%
1 Year
89.49%
2 Year
113.83%
Key data
Stock price
$24.01
P/E Ratio 
0.00
DAY RANGE
$23.61 - $34.30
EPS 
$0.00
52 WEEK RANGE
$13.74 - $47.45
52 WEEK CHANGE
$75.73
MARKET CAP 
4.627 B
YIELD 
N/A
SHARES OUTSTANDING 
100.401 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/28/2024
BETA 
1.36
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$872,062
AVERAGE 30 VOLUME 
$842,472
Company detail
CEO: Joshua T. Brumm
Region: US
Website: dyne-tx.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Dyne Therapeutics, Inc., a muscle disease company, focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Recent news